Iovance Biotherapeutics Inc (IOVA) concluded trading on Wednesday at a closing price of $2.23, with 24.57 million shares of worth about $54.8 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.42% during that period and on July 16, 2025 the price saw a gain of about 14.95%. Currently the company’s common shares owned by public are about 333.93M shares, out of which, 271.39M shares are available for trading.
Stock saw a price change of 12.06% in past 5 days and over the past one month there was a price change of -0.45%. Year-to-date (YTD), IOVA shares are showing a performance of -74.46% which decreased to -69.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.64 but also hit the highest price of $12.51 during that period. The average intraday trading volume for Iovance Biotherapeutics Inc shares is 14.18 million. The stock is currently trading 19.32% above its 20-day simple moving average (SMA20), while that difference is up 11.86% for SMA50 and it goes to -59.67% lower than SMA200.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) currently have 333.93M outstanding shares and institutions hold larger chunk of about 64.19% of that.
The stock has a current market capitalization of $744.67M and its 3Y-monthly beta is at 0.83. It has posted earnings per share of -$1.23 in the same period. It has Quick Ratio of 3.64 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IOVA, volatility over the week remained 11.25% while standing at 7.90% over the month.
Analysts are in expectations that Iovance Biotherapeutics Inc (IOVA) stock would likely to be making an EPS of -0.27 in the current quarter, while forecast for next quarter EPS is -0.25 and it is -0.71 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.34 which is -0.2 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.34 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 12.10% while it is estimated to increase by 32.36% in next year. EPS is likely to grow at an annualized rate of 45.16% for next 5-years, compared to annual growth of 4.17% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on July 15, 2025 offering a Sell rating for the stock and assigned a target price of $1 to it. Coverage by UBS stated Iovance Biotherapeutics Inc (IOVA) stock as a Neutral in their note to investors on May 16, 2025, suggesting a price target of $2 for the stock. Stock get a Buy rating from UBS on October 24, 2024.
